RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Theratechnologies Establishes New At-The-Market FacilityThat thought crossed my mind in fact that was brought up during the CC. In the past when they raised funds often they stated a reason for it but this ATM program's announcement didn't thus all the speculations. One would think with their oncology program could potentially expand to more therapeutic programs for various cancers , they might also have started working on more preclinical programs, Tesamorelin for cognition, Trogarzo IV push and future IM trial and of course NASH they already have ongoing and future potential projects which is a lot for a small company like THTX so I doubt this has anything to do with new projects. If you recall Paul said they are in position of strength re a partnership deal which some have questioned,now with those extra funds available they just added more strength to their position. I read generally speaking clinical trials can cost anything between 30 to 50 k per patient. I do recall they estimated some $25 millions for a phase 3 NASH with 900 cohorts which seems to be a bit low but the futility analysis with 400 patients shouldn't cost more than $20 millions. Now they had about $57 millions by end of May and generate revenues too and as per out beloved CFO the SGNA and R&D costs will be stable in the next couple of Qs. Having said that during the negotiations with a potential partner it's quite obvious there will be more funds needed to start the NASH alone as they have to fund other programs,with the extra ATM funds that weakness in their balance sheet is taken care of thus they won't need to accept a low ball offer.
Bucknelly21 wrote: Is anybody considered that they might be doing this because of a possible acquisition to add to the pipeline?